Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUDSON GI study of benralizumab in eosinophilic gastritis/gastroenteritis
NL-OMON50900Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benralizumab in eosinophilic gastritis (EG) and eosinophilic enteritis (EoN) (3 arms), sponsored by AstraZeneca. Primary endpoints: Histological response at Week 24 and Change from baseline in SAGED score at Week 24. Started Mar 2022; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic gastritis (EG)eosinophilic enteritis (EoN)
Beyond the preview
Go deeper on NL-OMON50900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50900.